Research has shown that there is a relationship between type 2 diabetes and cardiovascular disease, an umbrella of diseases that include damaged blood vessels, blood clots, and other issues. In patients with both chronic kidney disease (CKD) and type 2 diabetes, cardiovascular disease highly affects quality of life (QOL) and survival rates. However, shares Diabetes In Control, a drug called finerenone could be the key to addressing these issues.
According to the American Heart Association, common forms of cardiovascular disease include:
- Heart attack
- Heart disease
- Ischemic or hemorrhagic stroke
- Heart valve problems
In clinical trials, finerenone reduced cardiac failure and mortality rates in patients with type 2 diabetes and chronic kidney disease. Researchers want to continue evaluating how effective finerenone is in lowering the risk of cardiovascular disease in these patients.
5674 patients enrolled in one study, with an average follow-up time of 2.6 years. To enroll, patients had to be at least 18 or older with a heightened albumin-to-creatinine ratio. Patients were also required to have type 2 diabetes. Those with diabetic retinopathy, an ocular issue caused by diabetes, were included in the study. Additionally, patients were required to have taken either an ACE inhibitor or ARB for one month. Those with CKD who did not have type 2 diabetes were not included. Of the patients who enrolled, 46% (2610) had both type 2 diabetes and CKD.